Allogene Therapeutics ALLO 深 沪
等待开盘 11-26 09:30:00 美东时间
1.36
+0.010
+0.74%
华盛通- 最 高1.40
- 今 开1.34
- 成交量 250.27万股
- 最 低 1.30
- 昨 收 1.35
- 总市值 3.02亿
- 52周最高 3.78
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8621
- 委 比 -37.13%
- 总股本 2.22亿
- 历史最高 55.00
- 量 比 0.96
- 振 幅 7.41%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics' Dr. Michael Newman will present at the 3rd Donor Selection & Cell Source Summit in San Diego. His talk will focus on the Company's Decoy bacterial platform, which aims to address donor cell variability in allogeneic immune cell cancer therapy. Decoy20, the lead candidate, uses killed bacteria to trigger a broad immune response, enhancing the quality and consistency of immune cell products. Newman highlighted preclinical dat...
11-17 13:00
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
BioCardia reported Q3 2025 financial results and filed its 10-Q with the SEC. The company secured $6 million financing to support CardiAMP cell therapy approvals and the Helix delivery catheter submission. Clinical trials for CardiAMP in heart failure and chronic myocardial ischemia showed positive results, with ongoing enrollment in the Phase 3 CardiAMP HF II trial. The company plans a conference call to discuss these milestones.
11-12 21:40
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics will participate in three upcoming investor conferences in November and December to discuss its AlloCAR T™ product development for cancer and autoimmune diseases. The events include TD Cowen’s Immunology & Inflammation Virtual Summit on November 12, Jefferies Global Healthcare Conference in London on November 18, and Piper Sandler’s 37th Annual Healthcare Conference on December 2. Webcasts and replays will be available on th...
11-10 13:30
Allogene Therapeutics’ Earnings Call: Cautious Optimism
Allogene Therapeutics (($ALLO)) has held its Q3 earnings call. Read on for the ...
11-08 08:26
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lunai Bioworks Publishes Second-Gen Allogeneic Dendritic Cell Therapy In Vaccines Journal, Demonstrates Complete Pancreatic Tumor Regression In Humanized Mouse Models
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".LOS ANGELES, Nov. 5, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug
11-05 22:28
Ohio State University Added As New Clinical Site In Ongoing Phase 1 Trial Of IN8bio's INB-100, Donor-Derived Allogeneic Gamma-Delta T Cell Therapy
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added
10-29 20:05
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics announced on October 15, 2025, that its Compensation Committee granted stock option awards to 65 employees under the 2025 Inducement Plan. The awards total 1,093,300 shares with an exercise price of $1.49 per share, vesting over four years. Autolus is a biopharmaceutical company specializing in T cell therapies for cancer and autoimmune diseases. Contact: Amanda Cray at a.cray@autolus.com.
10-15 20:05
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement relat...
10-14 22:25
HYCROFT ANNOUNCES EXERCISE OF UNDERWRITERS' OVER-ALLOTMENT OPTION
WINNEMUCCA, Nev., Oct. 13, 2025 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or the "Company") announces, in connection with its previously announced public o...
10-14 05:30
